0
0
BioNTech and Pfizer have collected additional data on the safety and efficacy of their Covid-19 vaccine in adolescents 12 to 15 years of age.
According to the data, the vaccine’s adverse event profile was generally consistent with previous clinical safety data. No serious safety concerns were identified during the follow-up period of at least six months after receipt of the second vaccine dose, the companies said.
Vaccine efficacy against intensive stay at 93 percent
Efficacy of 100 percent against covid 19 disease was confirmed. “These additional data provide further confidence in the safety and efficacy profile of our vaccine in adolescents,” Pfizer CEO Albert Bourla said.
The data are expected to support planned applications for full marketing approval of the vaccine in this age group in the U.S. and also globally. In May, the vaccine from Mainz-based biotech BioNTech and its U.S. partner Pfizer received emergency approval in the U.S. and conditional marketing approval in the European Union for use in 12- to 15-year-olds.
- surce: k.at/picture:pixabay.com
This post has already been read 787 times!
